Pharma News

Researchers working with flies at IRB Barcelona describe that the concentration of some small intracellular organelles determines the branching capacity of tracheal cells.  Tracheal cells are analogous to the cells that form blood vessels in the human body. The inhibition or stimulation of new blood vessels has implications in cancer and in tissue regeneration.

Research in Veterinary Science reveals that vitamin D supplementation reduces the incidence and severity of tuberculosis (TB) in wild boar and red deer. The pilot study of 40 animals was conducted by a multidisciplinary team of scientists from the University of Surrey (UK), Universidad de Extremadura (Spain), and SME Ingulados (Spain).

Medtronic plc  announced that the U.S. Food and Drug Administration (FDA) has cleared the TrailBlazer(TM) angled support catheter for use in the peripheral vascular system. Support catheters such as the Trailblazer are often used in endovascular procedures treating complex peripheral artery disease (PAD).  FDA clearance was received on September 23, 2016.

Zymeworks Inc., and Daiichi Sankyo Company, Limited announced that they have entered into a cross-licensing and collaboration agreement to develop proprietary cancer immuno-oncology products

Aegerion Pharmaceuticals, Inc. announced that Japan's Ministry of Health, Labor & Welfare (MHLW) has approved Juxtapid for patients with homozygous familial hypercholesterolemia (HoFH).

[adsense:336x280:8701650588]

Daiichi Sankyo Company, Limited  announced that it has initiated a Phase 3 pivotal study of CS-3150 (esaxerenone (r-INN)), its non-steroidal, selective novel mineralocorticoid receptor (MR) antagonist, for patients in Japan with essential hypertension.

Daiichi Sankyo Company, Limited announced that safety and preliminary efficacy phase 1 data evaluating DS-8201a, a novel HER2-targeting antibody drug conjugate, will be presented during a late-breaking poster discussion session during the European Society for Medical Oncology (ESMO) 2016 Congress from October 7 -11 in Copenhagen, Denmark.

Medtronic plc  announced it has received U.S. Food and Drug Administration (FDA) approval of its MiniMed® 670G system - the first Hybrid Closed Loop insulin delivery system approved anywhere in the world. Featuring the company's most advanced algorithm - SmartGuard(TM) HCL - the system is the latest innovation in Medtronic's phased approach toward developing a fully automated, closed loop system.

Medtronic plc announced U.S. Food and Drug Administration (FDA) clearance of StealthStation® Cranial Software as an aid for deep brain stimulation (DBS) lead placement. The software is fully integrated with Medtronic's latest O-arm® Imaging System, providing clinicians with a complete procedural solution for the planning and placement of DBS leads. The announcement was made at the Congress of Neurological Surgeons (CNS) in San Diego.